Press Release
February 19, 2013
Contact: Michael P. Nagel
Tel. 480.921.4948
E-mail: mike.nagel@vomaris.com
Vomaris Announces initiation of study with Walter Reed National Military Medical Center’s Combat Wound Initiative:
CLINICAL AND MECHANISTIC DEMONSTRATION OF A BIOELECTRIC DRESSING SYSTEM FOR NON-HEALING WOUND MANAGEMENT:
A PHASE II RANDOMIZED TRIAL
Chandler, Arizona. – February 19, 2013 – Vomaris Innovations, Inc., a leading edge regenerative medicine company focusing on wound care with bioelectric technology, is pleased to announce the initiation of a new study with Walter Reed National Military Medical Center.
The objective of the study, funded by the Henry M. Jackson Foundation for the Advancement of Military Medicine, is the assessment of the clinical efficacy of a bioelectric dressing (Procellera®) in conjunction with standard-of-care on the healing rate of chronic soft tissue wounds compared with standard-of-care alone.
In this 50-subject study, the primary endpoint for efficacy will be the rate of healing (healing trajectory) in the treatment group compared to that of the control group, during the 12-week treatment study period. It is hypothesized that a bioelectric dressing will reduce wound healing time when compared to SOC treatment, thereby accelerating wound healing trajectory.
“Walter Reed’s selection of Procellera® for a study of this significance is an exceptionally positive indicator for the future of Vomaris, and our proprietary bioelectric technology,” said Michael P. Nagel, Vomaris President and CEO.
“Field experience along with our clinical studies continues to show that Procellera® has the potential to transform wound care as we know it today,” Nagel said. “Proving Procellera’s impact in a study associated with the Combat Wound Initiative will provide another layer of critical clinical evidence and establish our cost-savings footprint in the emerging medical device marketplace.”
Procellera® is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple indications.
For more information about Procellera®, please visit www.vomaris.com.
About Vomaris Innovations, Inc.
Vomaris Innovations, Inc., based in Chandler, Arizona, is a leading edge regenerative medical device
company specializing in bioelectrical field generating technologies for the wound care market. FDA
cleared, Procellera® is the world’s first wireless, self-contained antimicrobial wound device that
generates a sustained electrical microcurrent at the wound surface when activated with a conductive
fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure
ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites.
Randomized clinical trials are in process looking at other possible wound healing benefits for the use of
Procellera®.
For more information, visit www.vomaris.com or call 480.921.4948.
July 17, 2012
Contact: Michael P. Nagel
Tel. 480.921.4948
E-mail: mike.nagel@vomaris.com
Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
Chandler, Arizona. – July 17, 2012 – Vomaris Innovations, Inc, a leading regenerative medicine company focusing on wound care with bioelectric technology, has been granted another patent (U.S. Pat. No. 8,224,439) related ot its bioelectric technology surrounding the use of devices that rely upon reducing and oxidizing agents ot treat biologic tissue and promote healing.
"Our growing and valuable patent estate is indicative of the powerful momentum behind our leading bioelectric technology," said Michael P. Nagel, Vomaris President and CEO.
"Procellera® is transforming the way wounds are managed," he added, "which will create meaningful cost savings while enhancing the quality of patient care worldwide."
Procellera® is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple healthcare industries.
For more information about Procellera®, please visit www.vomaris.com.
About Vomaris Innovations, Inc.
Vomaris Innovations, Inc, based in Chandler, Arizona, is a regenerative medical device company specializing in emerging bioelectrical field generating innovative technologies for the wound care market. FDA cleared, Procellera® Wound Dressing is the world’s first wireless, self-contained antimicrobial wound dressing that generates a sustained electrical microcurrent at its surface when activated with a conductive fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites. Randomized controlled trials are in process looking at other possible wound healing benefits for the use of Procellera®. For more information, visit www.vomaris.com or call 480.921.4948.
# # #
February 20, 2012
Contact: Michael P. Nagel
Tel. 480.921.4948
E-mail: mnagel@vomaris.com
Vomaris Innovations, Inc. Names New CEO
Chandler, Arizona. – February 20, 2012 – Vomaris Innovations, Inc, a leading regenerative medicine company focusing on wound care with bioelectric technology, has named Michael P. Nagel as its new President and Chief Executive Officer. Mr. Nagel will also join Vomaris Innovations, Inc.’s Board of Directors. Mr. Nagel brings more than 26 years of sales, marketing and management experience in the medical device industry along with a visionary leadership approach. Before joining Vomaris, Nagel served as Chief Commercial Officer of Neomend. He has also served as Vice President of Sales and Marketing at Incisive Surgical and was co-founder and Vice President of Sales and Marketing at Vascular Solutions (VASC).
At Neomend, Nagel oversaw the commercial launch of a PMA device, Progel®, a pleural air leak sealant that quickly penetrated more than 1,200 hospitals and experienced rapid sales growth in the United States and Europe. He helped take Vascular Solutions from inception to IPO in 39 months and led the launch of a novel, biological vascular closure device into the interventional marketplace. With Incisive Surgical, Nagel led the launch of a new, absorbable skin closure technology, INSORB, built the entire distribution channel, sold INSORB to more than 1,000 U.S. hospitals and then launched the technology in Europe.
“With expertise ranging from diagnostics to cardiovascular devices, Nagel’s proven leadership skills in commercializing biological sealants, hemostats and biomaterials will drive the regenerative technology at Vomaris forward,” said Paul Foster, Chairman of Vomaris. “Mike brings the proven experience and leadership needed to accelerate the continued development and commercial launch of an innovative wound care technology. In addition, he brings unparalleled expertise in launching new technology into the medical marketplace that will help Vomaris expand its reach and become a global company,” continued Foster.
“I value the opportunity to work with an elite, highly focused team including employees and leading physicians who are dedicated to redefining wound care advancements,” Nagel said. “Driven by the increasing number of patients suffering from full-thickness wounds, there is a need to provide an advanced technology that will help expedite wound healing while reducing the associated pain and scarring. Vomaris is changing how wounds are managed, which will enhance the quality of patient care worldwide,” continued Nagel.
The Company’s product Procellera® is the first totally self-contained, comfortable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple healthcare industries. For more information about Procellera®, please visit www.vomaris.com.
About Vomaris Innovations, Inc.
Vomaris Innovations, Inc, based in Chandler, Arizona, is a regenerative medical device company specializing in emerging bioelectrical field generating innovative technologies for the wound care market. FDA cleared, Procellera® Wound Dressing is the world’s first wireless, self-contained antimicrobial wound dressing that generates a sustained electrical microcurrent at its surface when activated with a conductive fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites. Randomized controlled trials are in process to obtain clinical data for supporting expanded indications for use, including faster healing, reduced pain and decreased scarring. A recently published study in the Journal of Burn Care and Research on skin graft donor site wounds concluded that Procellera® healed wounds 35% faster and resulted in a significant decrease in scar appearance and improved patient subjective outcomes as compared to semi-occlusive control wound dressings. Vomaris’ ongoing research efforts are focused on evaluating additional benefits associated with emerging bioelectrical field generating technologies. For more information, visit www.vomaris.com or call 480.921.4948.
# # #
Media Contact:
(480) 921-4948
3100 W. Ray Rd. Suite 148
Chandler, AZ 85226